Neurosense Therapeutics Ltd. NRSN 深 沪
等待开盘 10-23 09:30:00 美东时间
2.44
-0.120
-4.69%
华盛通- 最 高2.5699
- 今 开2.55
- 成交量 1.86万股
- 最 低 2.15
- 昨 收 2.56
- 总市值 462.84万
- 52周最高 25.40
- 市盈率 静 --
- 换手率 0.98%
- 52周最低 2.15
- 委 比 -90.48%
- 总股本 189.69万
- 历史最高 163.60
- 量 比 0.57
- 振 幅 16.40%
- 历史最低 2.15
- 每 手 1
- 风险率 5.24%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NeuroSense Files U.S. Patent Application for Traumatic Brain Injury
Patent application seeks protection for PrimeC use in concussion, blast-related brain injury and chronic traumatic encephalopathy (CTE) Positions PrimeC for potential expansion beyond ALS in...
10-19 20:25
NeuroSense Therapeutics Announces Nasdaq Hearings Panel Date Of November 10; Minimum Bid Price Compliance Already Regained; Sees PrimeC Milestones In December And Q1 2027
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that its hearing before the Nasdaq Hearings Panel (the "Panel") is scheduled for...
10-13 20:38
SpaceX, Qualcomm and 3 Stocks to Watch Heading Into Monday
With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows: Space Exploration Technologies Corp. (NASDAQ:SPCX) shares rose sharply on Friday after Elon Musk’s rocket company completed three launches in less than 13 hours, sendin...
10-05 15:00
NeuroSense Provides Update on Nasdaq Listing Compliance
Company regains compliance with Nasdaq's minimum bid price requirement and intends to request a Nasdaq Hearings Panel hearing to seek additional time to regain compliance with the minimum ma...
10-03 04:15
美股大行评级 | 潜在涨幅919.61%！HC Wainwright上调NeuroSense Therapeutics目标价至52美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持NeuroSense Therapeutics"买入"评级，目标价从8美元升至52美元；HC Wainwright & Co.：维持艾切托"买入"评级，目标价从27美元升至34美元
09-29 08:33
NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
Management will participate in the 5th Annual ROTH Healthcare Opportunities Conference on September 29, 2026 and will be available for one-on-one investor meetings during the conference CAMB...
09-29 00:43
HC Wainwright & Co. Maintains Buy on NeuroSense Therapeutics, Raises Price Target to $52
HC Wainwright & Co. analyst Lander Egaña Gorroño maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy and raises the price target from $8 to $52.
09-28 18:20
NeuroSense Therapeutics H1 EPS $(2.10) up From $(3.70) YoY
NeuroSense Therapeutics (NASDAQ:NRSN) reported quarterly losses of $(2.10). This is a 43.24 percent increase over losses of $(3.70) per share from the same period last year.
09-26 04:33
美股大行评级 | 大行齐上调AI应用股目标价！Adobe、CRWD等获看好，慧与科技绩后现多空分歧
今日重点评级关注：BTIG：维持Climb Bio"买入"评级，目标价从20美元升至32美元；巴克莱：维持Alpha Tau Medical"超配"评级，目标价从17美元升至30美元
09-04 12:30
NeuroSense Announces Redesigned Development Plan For PrimeC In Amyotrophic Lateral Sclerosis, Structured To Reach Potential Path For Regulatory Submission And Faster Approval
Three-part program - AI-enabled characterization of PrimeC's formulation advantage, an active-comparator trial against edaravone, and a streamlined pivotal pathway - is designed to strengthen PrimeC's differentiation, shorten the time to potential commercialization, and significantly reduce overall ...
08-31 20:48
